Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine.
We report the case of a 61-year-old woman who developed an anaplastic CD30+ cutaneous T-cell lymphoma during oral cyclosporine (CsA) therapy for recalcitrant psoriasis. Two months after CsA discontinuation, clinical and histological resolution of the lymphoma was observed. However, 3 years later extracutaneous involvement of the lymphoma could be detected. The association between CsA administration and the occurrence of the lymphoma may be casual, but a relationship with immunosuppression may also be hypothesized. We have reviewed all relevant data in the literature. To our knowledge, this is the first case of primary cutaneous CD30+ anaplastic large T-cell lymphoma in a patient treated with CsA for psoriasis.
Corazza
M
M
Dipartimento di Medicina Clinica e Sperimentale, Sezione di Dermatologia, Università di Ferrara, Italy. czm@unife.it
Zampino
M R
MR
Montanari
A
A
Altieri
E
E
Virgili
A
A
D014408:Biomarkers, Tumor / Q000097:blood*; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D005050:Etretinate / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use; D017730:Ki-1 Antigen / Q000097:blood*; D016410:Lymphoma, T-Cell, Cutaneous / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012307:Risk Factors; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology
D014408:Biomarkers, Tumor; D007166:Immunosuppressive Agents; D007641:Keratolytic Agents; D017730:Ki-1 Antigen; D005050:Etretinate; D016572:Cyclosporine